Vicinitas Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $65M
Overview
Developing DUBTAC protein stabilizers for oncology and genetic disorders.
OncologyRare Disease
Technology Platform
Deubiquitinase Targeting Chimeras (DUBTAC) platform for targeted stabilization of disease-relevant proteins.
Funding History
1Total raised:$65M
Venture$65M
Opportunities
First-mover advantage in applying targeted stabilization to a wide range of loss-of-function diseases.
Risk Factors
Unproven novel modality with potential off-target effects and delivery challenges.
Competitive Landscape
Occupies a niche in protein stabilization versus the crowded field of protein degraders (PROTACs).